美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Cyclerion Therapeutics, Inc.

31.91

+7.3529.91%

盤後：31.19-0.7150-2.24%19:30 EDT

成交量：11.41萬

成交額：346.43萬

市值：14.52億

市盈率：-2.63

高：32.12

開：25.22

低：25.22

收：24.56

52周最高：59.36

52周最低：7.19

股本：4,550.00萬

流通股本：4,504.23萬

量比：3.56

換手率：0.25%

股息：- -

股息率：- -

每股收益(TTM):-12.1293

每股收益(LYR):-7.7700

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):-4.11

資料載入中...

總覽公司新聞公告

公司資料

公司名字：

Cyclerion Therapeutics, Inc.

交易所：

NASDAQ

成立時間：

2024

員工人數：

- -

公司地址：

221 Crescent Street,Building 23,Suite 105,Waltham,Massachusetts,United States

官網：

http://www.korsana.com

郵編：

02453

電話：

傳真：

- -

簡介：

Korsana Biosciences, Inc.於2018年9月6日在馬薩諸塞州聯邦註冊成立。Korsana Biosciences的成立是為了減輕患者和護理人員的神經退行性疾病負擔。與Paragon Therapeutics合作開發的Therapeutic Targeting是一種新型的血腦屏障穿透式穿梭平台，旨在實現大腦內部顯著更高的藥物濃度，並克服早期穿梭技術的限制。Korsana正在推進一系列針對神經退行性疾病的創新THETA療法，首先是用於治療阿爾茨海默病的KRSA-028。

董事

名稱

職位

Jonathan Violin

Chief Executive Officer and Director and President

Andrew Gottesdiener

Director

Heidi Henson

Director

Michelle Pernice

Director

Nimish Shah

Director

Tomas Kiselak

Director

股東

名稱

職位

Jonathan Violin

Chief Executive Officer and Director and President

Mark Vignola

Chief Financial Officer

Madelyn Zeylikman

General Counsel and Secretary

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/KRSA/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"KRSA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KRSA\",,,,,undefined,":{"symbol":"KRSA","market":"US","secType":"STK","nameCN":"Cyclerion Therapeutics, Inc.","latestPrice":31.905,"timestamp":1789156800000,"preClose":24.56,"halted":0,"volume":114119,"hourTrading":{"tag":"盘后","latestPrice":31.19,"preClose":31.905,"latestTime":"19:30 EDT","volume":1031,"amount":32421.05,"timestamp":1789169406451,"change":-0.715,"changeRate":-0.02241,"amplitude":0.02241},"delay":0,"changeRate":0.29906351791530955,"floatShares":45042270,"shares":45500000,"eps":-12.129334,"marketStatus":"休市中","change":7.345,"latestTime":"09-11 16:00:00 EDT","open":25.22,"high":32.12,"low":25.22,"amount":3464251.9399530003,"amplitude":0.280945,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-12.129334,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":24.56,"preHourTrading":{"tag":"盘前","latestPrice":24.56,"preClose":24.56,"latestTime":"09:20 EDT","volume":159,"amount":3872.700036,"timestamp":1789132809508,"change":0,"changeRate":0,"amplitude":0.022801},"postHourTrading":{"tag":"盘后","latestPrice":31.19,"preClose":31.905,"latestTime":"19:30 EDT","volume":1031,"amount":32421.05,"timestamp":1789169406451,"change":-0.715,"changeRate":-0.02241,"amplitude":0.02241},"volumeRatio":3.5624336442143325},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KRSA\",,,,,undefined,":{"symbol":"KRSA","floatShares":45042270,"roa":"--","roe":"--","lyrEps":-7.77,"volumeRatio":3.5624336442143325,"shares":45500000,"dividePrice":0,"high":32.12,"amplitude":0.280945,"preClose":24.56,"low":25.22,"week52Low":7.1862,"pbRate":"--","week52High":59.36,"institutionHeld":0,"latestPrice":31.905,"eps":-12.129334,"divideRate":0,"volume":114119,"delay":0,"ttmEps":-12.129334,"open":25.22,"prevYearClose":8.89,"prevWeekClose":29.75,"prevMonthClose":25.76,"prevQuarterClose":23.73,"fiveDayClose":34.72,"twentyDayClose":27.37,"sixtyDayClose":22.26},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KRSA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-09-09","symbol":"KRSA","defaultRemindTime":1788960600000,"type":"split","dateTimestamp":1788926400000,"forFactor":7,"toFactor":1,"ratio":7}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KRSA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KRSA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1789099200000},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1966002000,"yearFounded":2024,"address":"221 Crescent Street,Building 23,Suite 105,Waltham,Massachusetts,United States","zipCode":"02453","officePhone":"(781) 516-2325"},"stockCompanyDetail":{"websiteUrl":"http://www.korsana.com","stockEarnings":[{"period":"1week","weight":0.0724},{"period":"1month","weight":0.1627},{"period":"3month","weight":0.4024},{"period":"6month","weight":2.1433},{"period":"1year","weight":0.7874},{"period":"ytd","weight":2.5889}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Korsana Biosciences, Inc.於2018年9月6日在馬薩諸塞州聯邦註冊成立。Korsana Biosciences的成立是為了減輕患者和護理人員的神經退行性疾病負擔。與Paragon Therapeutics合作開發的Therapeutic Targeting是一種新型的血腦屏障穿透式穿梭平台，旨在實現大腦內部顯著更高的藥物濃度，並克服早期穿梭技術的限制。Korsana正在推進一系列針對神經退行性疾病的創新THETA療法，首先是用於治療阿爾茨海默病的KRSA-028。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.030269},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.005726},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.111354},{"month":4,"riseRate":0.428571,"avgChangeRate":0.134458},{"month":5,"riseRate":0.25,"avgChangeRate":-0.02829},{"month":6,"riseRate":0.5,"avgChangeRate":0.038893},{"month":7,"riseRate":0.375,"avgChangeRate":0.026358},{"month":8,"riseRate":0.625,"avgChangeRate":0.100342},{"month":9,"riseRate":0.375,"avgChangeRate":0.011718},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.324291},{"month":11,"riseRate":0.285714,"avgChangeRate":0.0186},{"month":12,"riseRate":0.428571,"avgChangeRate":0.106805}],"exchange":"NASDAQ","name":"Cyclerion Therapeutics, Inc.","nameEN":"Cyclerion Therapeutics, Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"KRSA\",market:\"US\",,,undefined,":{"directors":[{"name":"Jonathan Violin","position":"Chief Executive Officer and Director and President"},{"name":"Andrew Gottesdiener","position":"Director"},{"name":"Heidi Henson","position":"Director"},{"name":"Michelle Pernice","position":"Director"},{"name":"Nimish Shah","position":"Director"},{"name":"Tomas Kiselak","position":"Director"}],"executives":[{"name":"Jonathan Violin","position":"Chief Executive Officer and Director and President"},{"name":"Mark Vignola","position":"Chief Financial Officer"},{"name":"Madelyn Zeylikman","position":"General Counsel and Secretary"}]}}}